Oncolytics Biotech (ONCY) Competitors $0.90 +0.11 (+14.41%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.90 +0.00 (+0.44%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. TVRD, DBVT, CADL, SLRN, IMMP, DSGN, CMPS, ACB, BTMD, and CGCShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Tvardi Therapeutics (TVRD), DBV Technologies (DBVT), Candel Therapeutics (CADL), Acelyrin (SLRN), Prima BioMed (IMMP), Design Therapeutics (DSGN), COMPASS Pathways (CMPS), Aurora Cannabis (ACB), biote (BTMD), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Tvardi Therapeutics DBV Technologies Candel Therapeutics Acelyrin Prima BioMed Design Therapeutics COMPASS Pathways Aurora Cannabis biote Canopy Growth Tvardi Therapeutics (NASDAQ:TVRD) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk. Which has stronger earnings and valuation, TVRD or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than Tvardi Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTvardi Therapeutics$7.14M29.44-$70.87MN/AN/AOncolytics BiotechN/AN/A-$23.14M-$0.29-3.11 Do insiders & institutionals believe in TVRD or ONCY? 44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 3.1% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate TVRD or ONCY? Tvardi Therapeutics currently has a consensus target price of $71.50, indicating a potential upside of 218.34%. Oncolytics Biotech has a consensus target price of $4.33, indicating a potential upside of 380.95%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media favor TVRD or ONCY? In the previous week, Oncolytics Biotech had 5 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for Oncolytics Biotech and 0 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score. Company Overall Sentiment Tvardi Therapeutics Neutral Oncolytics Biotech Neutral Is TVRD or ONCY more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Tvardi Therapeutics' net margin of -595.39%. Oncolytics Biotech's return on equity of -313.77% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics-595.39% -710.04% -79.00% Oncolytics Biotech N/A -313.77%-130.19% Which has more risk & volatility, TVRD or ONCY? Tvardi Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. SummaryOncolytics Biotech beats Tvardi Therapeutics on 7 of the 12 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.73M$2.90B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-3.1121.5627.5820.25Price / SalesN/A281.07417.23118.60Price / CashN/A42.7336.8958.07Price / Book18.027.518.035.67Net Income-$23.14M-$55.05M$3.18B$249.21M7 Day Performance20.04%4.61%2.91%3.28%1 Month Performance170.73%4.72%3.72%5.56%1 Year Performance-12.52%5.92%36.04%21.13% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.2154 of 5 stars$0.90+14.4%$4.33+380.9%-10.8%$86.73MN/A-3.1130News CoverageHigh Trading VolumeTVRDTvardi TherapeuticsN/A$25.38-1.5%$71.50+181.7%N/A$237.58M$7.14M0.0080High Trading VolumeDBVTDBV Technologies3.7719 of 5 stars$8.56-8.9%$14.75+72.3%+209.4%$234.46M$4.15M-1.7480Analyst UpgradeGap UpCADLCandel Therapeutics2.4829 of 5 stars$4.67-1.7%$21.00+349.7%-19.2%$233.97M$120K-3.4960Analyst RevisionSLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135IMMPPrima BioMed1.0134 of 5 stars$1.52-5.0%$7.00+360.5%-13.6%$221.98M$5.14M0.002,021DSGNDesign Therapeutics0.3795 of 5 stars$3.90+4.3%$4.00+2.6%+18.2%$221.40MN/A-3.9440CMPSCOMPASS Pathways1.6502 of 5 stars$2.35-49.2%$17.00+623.4%-48.0%$219.87MN/A-1.18120Gap UpHigh Trading VolumeACBAurora Cannabis0.2821 of 5 stars$3.91-4.2%N/A-6.6%$219.78M$246.72M35.551,073BTMDbiote2.6798 of 5 stars$4.01+1.3%$8.00+99.5%-43.1%$219.39M$197.19M6.57194News CoverageCGCCanopy Growth2.8038 of 5 stars$1.19-4.0%$2.00+68.1%-80.0%$218.80M$269.00M-0.293,150 Related Companies and Tools Related Companies Tvardi Therapeutics Competitors DBV Technologies Competitors Candel Therapeutics Competitors Acelyrin Competitors Prima BioMed Competitors Design Therapeutics Competitors COMPASS Pathways Competitors Aurora Cannabis Competitors biote Competitors Canopy Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
